Bayer AGXSWX:BAYN 48 14-Day RSI is 88.21 as of Jun. 30, 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 48/100 and a GF Value™ of CHF24.74 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,046 Drug Manufacturers companies, Bayer AG ranks worse than 96.75% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-06-30), Bayer AG's 14-Day RSI is 88.21.
The industry rank for Bayer AG's 14-Day RSI or its related term are showing as below:
XSWX:BAYN's 14-Day RSI is ranked worse than 96.75% of 1046
companies
in the Drug Manufacturers industry
Industry Median: 46.275
vs XSWX:BAYN: 88.21
Bayer AG (XSWX:BAYN) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Bayer AG 14-Day RSI Related Terms
XSWX:BAYN vs LLY, JNJ, ABBV: 14-Day RSI Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Bayer AG's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (XSWX:BAYN) has a 14-Day RSI of 88.21 as of Jun. 30, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Bayer AG and its competitors. According to the industry distribution chart, Bayer AG ranks #1012 out of 1046 companies in the Drug Manufacturers industry, placing it in the top 96.7%.
Is Bayer AG's 14-Day RSI too high?
Bayer AG's current 14-Day RSI is 88.21. The Drug Manufacturers industry median 14-Day RSI is 46.28. Bayer AG's value of 88.21 is 90.6% above this industry median. Based on the distribution chart, Bayer AG ranks #1012 out of 1046 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bayer AG has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's 14-Day RSI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #1012 out of 1046 companies for 14-Day RSI. This places Bayer AG in the lower half of its industry. The industry median 14-Day RSI is 46.28. Bayer AG's value of 88.21 is 90.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 46.28, based on 1,046 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current 14-Day RSI of 88.21 is 90.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 46.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current 14-Day RSI is 88.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.74, compared to a current price of CHF42.49 — trading 71.7% above its estimated fair value. The current 14-Day RSI is 88.21 and 90.6% above the Drug Manufacturers industry median of 46.28. Bayer AG's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current 14-Day RSI is 88.21 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF42.49 is trading 71.7% above its estimated GF Value™ of CHF24.74.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
14-Day RSI: 88.21
GF Value™: CHF24.74 vs. price of CHF42.49 (71.7% above fair value)
Industry Position: 90.6% above the Drug Manufacturers median (#1012 of 1046)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
48GF Score
Get the complete analysis for XSWX:BAYN
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 